News and Events, Recent News

BriaCell Announces Non-Brokered Private Placement

BriaCell Therapeutics Corp. (TSX VENTURE:BCT)(OTCQB:BCTXF) (“BriaCell”, the “Company”, or “BCT”) announced today that it intends to complete a non-brokered private placement (the “Offering”) of units of the Company (the “Units”) at a price of $0.20 per Unit for aggregate gross proceeds of up to C$600,000. The Offering is in addition to the Company’s proposed strategic […]

Recent News

BriaCell Announces Proposed Investment by Leading US Biotech Fund – Company Plans to Seek NASDAQ Uplisting –

Berkeley, CA and Vancouver, BC – April 22, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has entered into an agreement with a leading US biotechnology fund for an investment of C$650,000. The subscription agreement of units (“Units”) is priced at C$0.19, each […]

News and Events, Recent News

BriaCell Files a Patent Application to Protect Additional Cancer Vaccines with Genetic Features Thought to Promote Strong Anti-Tumor Activity

– Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 – Berkeley, CA and Vancouver, BC – April 12, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) is very pleased to announce that it has filed a provisional patent application with the U.S. Patent and Trademark Office […]

Recent News

BriaCell Targeting Launch of Its Phase I/II Clinical Trial During Current Quarter

BERKELEY, CA and VANCOUVER, BC–(Marketwired – April 05, 2016) – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)(TSX VENTURE: BCT) (BCTXF) is very pleased to provide an update in regard to the planned timing of its Phase I/II clinical trial for up to 24 late-stage cancer patients. BriaCell has spent a great deal of time and […]